International Journal of Applied and Advanced Multidisciplinary Research (IJAAMR)
Vol.3, No.9, 2025: 591-610

Circadian Rhythm Disruption as a Driver of Tumor Aggressiveness: Chrono Oncology Based Treatment Strategies

Sayma Nasrin Shompa
International Islamic University
Corresponding Author: Sayma Nasrin Shompa Saimanasrin453@gmail.com

A R T I C L E I N F O

Keywords: Circadian Rhythm, Chrono-Oncology, Tumor Aggressiveness, Cancer Chronotherapy, Biological Clock

Received : 5 July
Revised : 23 August
Accepted: 23 September

©2025 Shompa: This is an open-access article distributed under the terms of the Creative Commons Atribusi 4.0 Internasional.

A B S T R A C T

The circadian rhythm, which is governed by superchiasmatic nucleus (SCN) and peripheral oscillator, controls many physiological processes, including cell cycle progress, DNA repair and immune monitoring. The disintegration of this rhythm, whether lifestyle factors, genetic changes, or environmental stimuli, is implicated in the progression of oncogenes and tumor. Recent progress in chrono-acquisition highlights the ability to align cancer treatments with circadian biology to increase efficacy and reduce toxicity. This paper reviews mechanically relations between circadian disintegration and tumor aggression and examines chrono-modulated treatment strategies for individual oncology care. Circadian rhythm, which is orchestrated by superchiasmatic nucleus and peripheral oscillator, is integral to regulate cellular proliferation, DNA repair and immune defense. The disintegration of these rhythms - through genetic mutation, lifestyle patterns, or environmental stresses - is rapidly recognized as the driver of tumor initiation and progress. The task examines the mechanical routes connecting circadian disagrees to increase the aggression of the tumor, including genomic instability, impaired immune monitoring, and converted hormonal balance. The emerging region of chrono-imagology is emphasized, which takes advantage of temporary biology to adapt to cancer treatments. Strategies such as Circadian-Man-Charan-specific chemotherapy administration, biomarker-directed treatment scheduling, and molecular clock-goal agents are reviewed, while reducing toxicity and reviewing for their ability to maximize medical efficacy by reducing poisoning. By integrating insight from pharmacokinetic, pharmacodynamics and translation oncology, this study underlines the need to align treatment with a patient's biological clock. To overcome the challenges of clinical implementation, it will be important to translate chrono-oncology from research in mutual variability and limited biomarker verification-naval clinical practice in the circadian phase. Recent progress in chrono-acquit sheds light on the ability to align cancer treatment with Circadian biology

DOI: https://doi.org/10.59890/ijaamr.v3i9.107
ISSN-E: 3026-2437
https://nvlmultitechpublisher.my.id/index.php/ijaamr

INTRODUCTION

Circadian are endogenous, there are about 24-hour oscillations that regulate various physical and behavioral processes, including sleep-vegetarian cycles, metabolism, cell proliferation, DNA repair and immune functions. These rhythms are generated by transcriptional -transcriptional feedback loops, including core clock genes such as clock, BMAL 1, per, and Cry [1,2]. Under normal conditions, this molecular clock synchronizes internal biological processes with external environmental signals, especially the light -Dark cycle, ensuring hemostasis [3]. However, chronic disintegration of the circadian rhythm-is firmly associated with the initiation and progression [4,9,11] due to factors such as irregular sleep patterns, or genetic changes. Oracularly, the circadian misalignment contributes to genomic instability, impaired DNA repair capacity, converted cell cycle regulation, immune suppression, and metabolic/hormonal dishes, promoting all tumors of aggression [5-8,22]. For example, melatonin and cortisol play an important role in two circadian-regulated hormones, tumors suppression and inflammatory control; Their disguise creates a pro-tumor microelement [7,8].

Provide studying and evidence of epidemiology, confirming the long -term shift with large -scale cohort analysis that the work of the long -term shift is associated with an increase in risks of breasts, prostate, colorectal and gastrointestinal cancer [9–11]. While reflecting this evidence, the International Agency for Research on Cancer (IARC) has classified the rebellion disintegration from night-shift work as "probably carcinogenic to human" (Group 2A) [11]. Thus, the circadian misalignment is now recognized as an important and convertible risk factor for cancer development. In recent years, the emerging region of chrono-acquisition has focused on exploiting the circadian biology to adapt to cancer therapy [12–14]. Studies suggest that the time of chemotherapy, radiotherapy and immunotherapy may increase medical efficacy by reducing toxicity relative to the patient's circadian phase [12,18]. For example, clinical trials in colorectal cancer have shown better results when chemotherapeutic agents are distributed to Sinkoni with DNA synthesis and metabolism [12,19]. Wearable biosensor, artificial intelligence, and pharmacokinetic/pharmacodynamic (PK/PD) modeling advances are enabling the privatization of further chronotherapy [13,16,19]. Additionally, the pharmacological approach is in the form of novel-Antti-cancer strategies [14,15] under active investigation to target watch components (e.g., REV-CK1/of inhibitors). Despite these promising developments, there are important challenges in translating the circadian biology to regular clinical oncology. These include inter-individual variability, practical boundaries of hospital scheduling, and incomplete verification of Circadian Biomarker [16,20] in the circadian phase. To overcome these obstacles, molecular biology, oncology, bio -engineering and computational modeling require multi -kissing cooperation. This paper reviews the mechanical relationship between circadian disintegration and the aggression of the tumor, highlighting the role of genomic stability, immune monitoring, and the role of circadian regulation in metabolic homeostasis. In addition, it examines the chrono-oncology-based treatment strategies, including customized drug delivery programs, biomarker-

directed chronotherapy, and circadian clock-targeting agents, aims to improve medical results and reduce the toxicity associated with treatment.

Table 1. Data Collection

Case study (category)	Modality/ route of administration	Indication	First time in human (Year)	Evaluation phase	PK method	Exposure within twofold?	Dose within twofold?	Endpoint	Comment
3 (2)	NCE/PO	Immunology	<2007	II	PBPK	Y	Y	Efficacy	In-licensed after Phase I
	NCE/IV	Oncology	<2007	III	PBPK	Y	NA	Efficacy	No modelling-based dose prediction. No efficacy in dose range tested. In-licensed after Phase I
	NCE/PO	Immunology	<2007	III	PBPK	Y	NA	Efficacy	No modelling-based dose prediction: animal models not valid

Case study (category)	Modality/ route of administration	Indication	First time in human (Year)	Evaluation phase	PK method	Exposure within twofold?	Dose within twofold?	Endpoint	Comment
2 (2)	**NCE/IV**	Oncology	<2007	I	Allometry	Y	↓	Efficacy	No efficacy in dose range tested
	NBE/SC	Immunology	<2007	I	Allometry	Y	Y	Efficacy	Empty Cell
	NCE/PO	Oncology	2008	I	Allometric	↓	↓	PB/Efficacy	
	NCE/PO	Oncology	2009	I	Allometric	Y	Y	PB/Efficacy	Note
	NBE/SC	Oncology	2011	I	Allometry	↑	NA	Efficacy	No modelling-based dose prediction. No efficacy in dose range tested
	NBE/IV	Immunology	2013	I	Allometry	Y	↓	Efficacy	Empty Cell
	NBE/IV	Oncology	2013	I	allometry	Y	Y	PB/efficacy	
	NCE/PO	Oncology	2013	I	PBPK	↑	↓	PB/Efficacy	
	NCE/PO	Immunology	2014	I	allometry	Y	Y	PB/Efficacy	

Case study (category)	Modality/ route of administration	Indication	First time in human (Year)	Evaluation phase	PK method	Exposure within twofold?	Dose within twofold?	Endpoint	Comment
1 (1)	NBE/IV	Oncology	2015	I	Allometry	Y	Y	PB	
	NCE/PO	Oncology	2016	I	PBPK	Y	↓	PB	Empty Cell
4 (3)									
	NCE/PO	Oncology	2017	I	PBPK	Y	↓	PB	No biomarker modulation

LITERATURE RIVIEW

One. Correspondence: DB; Distal Biomarker; IV, intravenous administration; No, not applicable; NCE, new chemical unit; NBE, new biological unit; PB, proximal biomarker; PO, Peral Administration; SC, under leather administration;

a. Overprediction; ↓ under pandiculation.
b. No historical prediction is available, according to Yamagata et al, the prophecies of withdrawal, based on two to three species, according to the Oi-Tozer method, the volume of the distribution, fraction intestine metabolism, and fraction was accepted as 0.9
c. Multisector Allometry.
d. Cynomolgus monkeys 15, 16 to single species Allometry. Yamagata et al. According to the clearance prediction, the volume of distribution according to the OE-Teaser method based on the two to three species, the estimated fraction using the Gut model, the estimated absorption was using intestine metabolism, standard PBPK model circadian rhythms are endogenous, about 24-hour oscillations in biochemical, physical and behavior processes These rhythms are controlled by a core molecular clock consisting of transcriptional-translation feedback loops, which include genes such as clock, BMAL 1, per, and Cry. The chronic misleading of these rhythms, as seen in shift workers or irregular sleep-aging patients, is associated with cancer risk and poor-relieved. Circadian rhythm cell cycles control physical

processes including progress and DNA repair. Disintegration is implicated in oncogenesis. [1,2,4,6,9,11,25]

Section 1A: System of Cycadean Disintegration

a. Genomic instability - core circadian clock genes (e.g., clock, BMAL 1, per, cry) regulate DNA repair and cell cycle control. Their disintegration weakens DNA damage reactions, causing mutation and uncontrolled spread. [4, 6, 25].
b. Immune Daman-Discarder Circadian Lyre's Cytotoxic T-Cell and Natural Killer (NK) reduce cell activity. This allows impaired immune monitoring tumors to detect and avoid growing. [6, 29, 39]
c. Metabolic disintegration - Missing of melatonin and cortisol rhythm changes antioxidant defense, inflammation and angiogenic. As a result, hormonal imbalance makes a microelement promoting a tumor. [7, 8, 30]

Section 2 A (Epidemic):

Large-scale cohort studies suggest that people working in long-term night or rotating shifts face 20–40% higher risk of developing cancer such as breasts, prostate, colorectal and gastrointestinal tumors. [9,10,34] Because circadian rhythm disintegration is an important underlying factor, the International Agency for Research on Cancer (IARC) has officially classified the night-shift work as a group 2A carcinogen-which means "probably is carcinogenic for humans". It presents circadian Misalignment as an important and variable cancer risk factor.[11]

Section 3A (Treatment Strategies):

a. The effectiveness and toxicity of chrono-chemotherapy-chemotherapeutic drugs varies with the time of the day they administer. For example, specific circadian stages (e.g., evening, combine with peak DNA synthesis in tumor cells) increases anti-cancer efficacy by reducing side effects. [12, 18, 46]
b. Biomarcker-wardians such as body temperature, cortisol rhythm, or activity cycles help determine the optimal treatment window. Wearable equipment and digital health equipment now allow the real -time monitoring of these rhythms, enabling more individual drug schedules. [13, 17, 45]
c. Watch-targeted drugs-novel agents target the circadian clock components directly. For example, RV-CK1 inhibitors and CK1 inhibitors can recreate tumor watches, restore immunity monitoring, and even coordinate with immunotherapy to promote anti-cancer reactions. [14, 43, 47]

2. Human Pharmacokinetics Predict

Human PK predictions were made according to standard principles (Table 1). Primary human PK parameters (clearance and distribution volume) for large molecules were predicted using single-species allometry based on cynomolgus monkeys, which is successful to reduce the effects of immune reactions for human antibodies in humans This approach is successful when the approach is successful when the linear is success (TMDD) is not relevant, as is for binding antibodies for soluble antigens (e.g., cytokines). However, monoclonal antibodies (MAB), with their high affinity and target specificity, are likely to have low therapeutic doses and the effect of TMDD on exposure cannot always be considered negligible. When the dose is low and TMDD cannot be ignored, it is necessary to translate the mechanical model involving TMDD. Human PK

predictions were designed using modern methods for the oldest compounds, for which PK predictions were not available (Table 1**).** [15, 16]

Human PK predictions for small molecules were done with methods developed with science in the region (Table 1). Therefore, the old predictions used allometric scaling to assess human evacuation, resulting in minor overs stems, while recent compounds used extrapolation from in vitro systems. The volume of the distribution was estimated using a combination of the allometric and tissue structure models, which develops towards the use of the Oi-Teaser model intestine metabolism, important in only two compounds of the data set. This was estimated to be for these two compounds using the 'Gut method', which is reported to be acceptable accuracy.

3. Human Active Dosage Prediction: Current Challenges and Future

In diagnostic chrono-ecology, two major challenges limit implementation:

a. Inter-personal variability-each patient's circadian rhythm is different due to genetics, lifestyle or environment. This makes it difficult to define the time of "universal" treatment as optimal medical window may vary widely among patients.
b. Biomarker verification - reliable circadian biomarker (e.g., melatonin rhythm, cortisol levels, body temperature cycles) are still under investigation. Without valid and standardized biomarker, it is difficult to properly determine the patient's circadian phase and personalize treatment time [16, 17, 41]

a. Tumor Micro -Verse and Circadian Reprogram of Medical Implications

Tumor -linked macrophages (TAMS) undergo an immunosuppression and metastasis promoting circadian reprograming. Inhibited in TAMS, circadian lyrical secretions change the scrape pattern, disturb immunity and facilitate immunity (Gupta et al., 2023). It is increased in shift workers, where the chronic circadian induces the missing, metabolic dysfunction - including insulin resistance and dyslipidemia - a permissible microincubation for the progression of the tumor (waiter et al., 2022). [22,23].

b. Chrono Nutrition and Metabolism

Time-related feeding (TRF) emerges as a non-dominated strategy to combat circadian disintegration. By restricting calorie intake for circadian -focused windows, TRF restores metabolic oscillations, reduces systemic inflammation, and insulin/IGF -1 Pathway can suppress tumor spread through modulation (Panda, 2024). This approach synergies with the melatonin receptor agonist, which re-activates the Circadian-regulated tumor suppression mechanism (Hofman et al., 2023) and reactivates anti-angiogenic and pro-apoptotic effects. [24,28]

c. Treatment Efficacy Regulation of Efficacy

The time of cancer remedies greatly affects the results:

- Chemotherapy is toxicity is circadian-modulated, with DNA repair efficiency and drug metabolic routes perform time-subsequent activity. The administration of chemotherapeutics during peak DNA synthesis stages (e.g., 5-FU) reduces off-target toxicity by increasing tumor selectivity (Sainker et al., 2023). [26]

- Radiotherapy efficacy improves when circadian-regulated DNA damage is aligned with reaction peaks. Organized reviews reduce normal tissue toxicity and improve tumor control in the chrono-radiotherapy protocol (Blackman et al., 2021).[40]

d. Molecular Goal and Synthetic Modulator

Core clock component current actionable target: Per2 cells serve as a tumor mitigation in glioblastoma by regulating the cycle posts and apoptosis routes. It's down gradation accelerates the aggression of the tumor (Ruan et al., 2022).[27]

The CRY2 stabilization promotes the adenocarcinoma growth of the lung by interrupting tumor repression (Richards et al., 2022) [35] of CRY2 stabilization P53.

Synthetic circadian modulator (e.g., Rev-ARB agonists) are in development to revive peripheral oscillator, showing promise in reversing immune theft and restoring medical sensitivity (Sold et al., 2024; Gachon et al., 2021).[37]

e. Metabolism and Dietary Intervention

Recent advance tumors highlight the important role of metabolic oscillations in cells, which are powered by circadian-regulated routes that affect the use and metabolic processes of nutrients [31]. These oscillations create temporary weaknesses in cancer metabolism that can be patiently exploited. For this, time-related feeding (TRF) has emerged as a non-pharmacological intervention; Clinical studies suggest that restricting calorie intake for circadian-edged windows improves results in cancer patients by synchronizing metabolic homeostasis and reducing tumor proliferation [32]. However, TRF efficacy is compromised by the circadian desynchrony, which increases metabolic syndrome and creates a permissible environment for the progression of the tumor [36]. In particular, disgusting insulin/IGF-1 signaling in the signaling tumor inhibit the consistency, further accelerates cancer growth and medical resistance [48].

f. Circadian Disintegration and Cancer Risk

Epidemiological figures confirm that shift work increases the risk of gastrointestinal cancer by 20–40%, which is responsible for the chronic circadian misalignment [34]. This disintegration promotes cardiometabolic comorbidities (e.g., insulin resistance, hypertension) that increases cancer incidence and aggression [38]. Oracularly, the bmal1 deficiency macrophages in tumor microinequities provide metastasis by improving anti-tumor immunity [39], while persistence circadian watches in stromal cells affect the tumor-stroma cross stock to drive the progression [42].

METHODOLOGY

Translation of Pregnant PK/PD Studies for Humans: Apply Translating Best Practice Embodied in TXM Guide

In order to apply TXM best practices in translation PK/PDs, a suitable disease animal model is required to be selected and verified by using a tool compound before testing novel drugs. Early pilot studies use single high doses and limited biomarkers to assess acute efficacy, followed by dosage -exposer -proposal relationships and sub -or chronic PD studies to define effective

plasma/target concentrations. Repeated doses account for tolerance, sensitization, or mediation of CYP for autoinduction/prohibition. The sample time points are designed to capture the full PK/PD profile, including the offset of starting, duration and effects. Control groups and matched satellite groups are used when PK and PD cannot be measured in the same animals. Integrating these figures helps identify human-relevant target modulation for efficacy, a practice that was not always implemented in earlier programs.[42]

RESULT

Human Active Dosage Predicts: Performance Evaluation

We evaluated active human doses for 15 compounds using TXM guides in various medical fields and administration routes. For a compound, phase II dose selection used the maximum-tolerant dose (MTD) approach. Two compounds lacked PD biomarkers, which prevents the prediction of active doses. In the remaining 12, seven compounds predicted the dose within two times the clinical dose, while five times had left two times, often the effective doses were underestimated. The compounds were classified based on the TXM guide reactions: Category 1 (both doses related to "yes") predicted active doses, while Category 2 (both "no") showed low success. Case Study 1 (Category 2) gives the example of translative best practices: compound A, a syngeneic breast tumor is tested in mouse model, which produces intact immune, rapid and old PK/PD data tumor and human dose in PBMC to guide the human dose estimates. Clinical dose decapitation confirmed the target occupancy, achieved medium clinical effects within two times the predicted dose, reflecting effective.

Table 2. TMX Guide Questions (Q) Correlation Dose Prophem with Effectiveness

Category	Q1: desired exposure–response in appropriate animal model?	Q2: Translatable biomarkers?	Number of drugs for which model-based active dose prediction is within twofold or clinical efficacy is observed within predicted dose range out of total number in category
1	Yes	Yes	5/6
2	No	No	1/6
3	No	Yes	2/2
4	Yes	No	0/1

For A. Cladribine (Case Study 3), Phase II dose was based on clinical evaluation, not pre-genuine PK/PD modeling. For other five compounds, the approximate dose was lower than the phase II dose or showed limited clinical efficacy. There was no active dose prediction in a compound, as MTD -directed phase II selection.

B. A compound had no active dose prediction and no efficacy was shown within the tested dose range. [42]



Figure 1. Syntonic Breast Cancer Model

(A) displays more reactions with a decrease in tumor growth by compound A by compound A for control in a syngeneic mouse model, individually with bifurcation than targeting portions. (B) Relating of tumors of treated mice did not produce tumor tumors. PBS: Phosphate buffer saline.

Box 1
Case Study 1 (Category 1): Getting accurate human dosage prediction through translational best practices
Background: Different fusion proteins for oncology were tested in a syngeneic breast tumor mouse model; The target is measured in both tumors and PBMCs.
Preclinical modeling: Mouse PK/PD and PK/Effectiveness Studies determined the required concentrations for tumors and PBMC target engagement.
Human translation: Initial clinical trials confirmed the target occupancy; The predicted human exposures were within 2 × of the real, showing moderate clinical effects.
core lesson: Translation reliability improved into pathological animal models. The alignment of biomarker enables dosage prediction from both tumors and blood. Integrating PK/PD with efficacy data reduces uncertainty in clinically relevant doses.



Figure 2. Translation Of PK/PD/Effectiveness to Obtain Human Doses

PK/PDs and PK/Effective models in mice can be integrated to achieve the level of occupancy required for efficacy in PBMC and tumors. Human doses are obtained from translated PK/PD and PK/Effectiveness Models. PD, pharmacodynamics; PK, pharmacokinetics; TGI, Tumor Development Prohibition; To, to target occupancy; PBMC, peripheral blood mononuclear cells.

Box 2
Case Study 2 (Category 2): High uncertainty in the approximate dose range in the absence of an appropriate animal model.
Background: The compound B, a bipolar nanobody, which targets two cytokine isoforms involved in autoimmune diseases, showed efficacy in the Cynomolgus monkey CIA model, but lacking a quantitative PK/PD relationship.
Translation challenge: Without a PD biomarker, the prediction of human dose depends on the same analogy of the same monoclonal antibodies, resulting in a comprehensive estimated dose range (0.03–240 mg).
Learned learning: A suitable animal model and lack of PK/PD data creates high uncertainty. Cross-indication translation is risky without disease-specific mechanical data. It is important to establish quantitative PK/PD relations and valid biomarkers for accurate human dose.

Representative of Case Study 2 (Box 2), Category 2 shows the importance of creating a PK/PD (effective) relationship in an animal model that is relevant

to the signal that is believed to be. Compound B was tested in a pre -of chronic disease model, which was for arthritis, but was tested in patients with a separate autoimmune position. The estimated dose range was widespread, which reflects uncertainties in translation in another autoimmune position from monkey collagen-inspired arthritis (CIA) model. Even though the targeted cytokine mediated both diseases, but may be specific to the interaction indication of the downstream effects after the cytokine activation with its local environment. Given the widespread predicted human dose range, effective doses in humans were estimated based on marketed MAB targeting a similar cytokine.



Figure 3. Plan I - PK/PD Model (Compound B)

The human preventive dose was estimated from a monkey collagen-inspired arthritis model. Using a PK/PD approach with the first-order rate constant Scrutiny Kin and K out K_{out}Kout.,

Case Study - Cladribine (Category 2, Table 2): Phase II dosage was directed by clinical evaluation rather than pregnant PK/PD. In a rodent EAE model, Cladribine showed no clear effect, possibly due to the difference of species affecting the active metabolite levels at the site of action. Lack of limited verification of a proximal biomarker of the model. This highlights the need to maintain flexibility in intersection and translation strategies for biological differences.[42]

Box 3
Case Study 3 (Category 2A): Difference of species led pregnant failure
A nucleoside analog cladribine showed no clear advantage in the rodent EAE model, possibly due to species-specific differences in metabolism and tissue distribution. The lack of a proximal PD biomarker made it impossible to determine whether the incompetence was due to drug or insufficient risk. Clinically, the drug was active, revealing that the rodent model underestimated the human response.
Lesson: Understand the biology of the species before relying on animal efficacy data. Use translative PD biomarkers to explain poor pre-pregnant results and avoid rigid "one-shaped" approaches.

Table 3. Dosing Schedule of Cladribine

Year	**Month**										
Empty Cell	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**
1	4–5 days	4–5 days										
2	4–5 days	4–5 days										
3												
4												

Case Study 4 (Box 4) suggests that human dose can be successful by using target engagement data from an approved drug, even without a translational pre -of pre -pregnant efficacy model. Compound C, designed with better tolerance, gained 90% receptor occupancy in in vitro, and its PK/PD modeling in mice made accurate prediction of the human dose range. Clinical data confirmed both the receptor occupancy and efficacy.

Box 4
Case Study 4 (Category 3): Successful human dose prediction is possible with the knowledge of the target engagement of an approved drug for a clinically valid target, even in the absence of a pre -pricing efficacy model.
Compound C, an oral small molecule targets a clinically valid oncology target, achieved successful human dosage predicted despite a deficiency of a pregnant efficacy model. Known> Using data from an approved drug with 90% target engagement, a PK/PD model in which irreversible binding was included, predicted a safe, effective dose that receives 93–97% receptor occupancy. Phase I PBMC measurements confirmed the target engagement, and 86% of patients showed disease control, including complete reactions at the highest doses.
Lesson: When a target engagement is set up for efficacy in humans, the pre -of pregnancy models are not necessary for dosage.



Figure 4. Translation Receptor Executive Model (A)

The mouse receptor occupancy data was modeled. (B) Human model predicted the dose range that receives high receptor occupancy. For category 1 compounds, active doses were predicted, which was twice distracted, explained by the exposure underprediction. For Category 2, PK predictions were within two times, indicating pharmacology misunderstanding dosage errors, not exposure exception. This highlights translational guidance, clinically valid PD biomarker's use and the need to understand the difference of species in pharmacology and the need to understand the differences of the species when predicting human doses.



Figure 5. Decision to Decide Between Maximum/Minimal/Average Stable-State Concentrations as a Pharmacokinetic (PK) Metric for Efficacy

Figure V, the selection between maximum, minimum, or average stable-state concentrations as PK MT for efficacy is challenging due to PD and biomarker uncertainties, often crossing PK variability. Translating animal models in humans is limited by species difference, reference to tumor and biomarker access. Along with dosage calibration and Monte Carlo simulation - imaging and circulating biomarkers, can improve predictions. PK/PD modeling, valid biomarker, disease biology and integrating AI-operated scheduling can optimize individual doses.[42]

12.Clinical Translation and Medical Strategies

Chronotoxicology clinical trials require innovative designs to address inter-class variability in the circadian rhythm. Adaptive protocols that integrate real -time biomarker monitoring (e.g., cortisol, body temperature) are required to personalize the time of treatment [33]. For example, Cronos-Flory Regiment-which shows significant existence benefits in metastatic colorectal cancer by optimizing drug efficacy by reducing chemotherapy-toxicity to peak DNA synthesis cycles [46]. Pharmacically, REV-CK1 and/or inhibitors re-shape peripheral circadian, restoration of tumor-dominated functions and checkpoint inhibitory efficacy [44]. These agents re-activate the immune monitoring route [44] and induce tumor-specific apoptosis. Additionally, the AMPK core stabilizes the circadian clock, which presents a dual target for metabolic regulation and circadian reprograming [49]. Emerging synthetic circadian modulator provides accurate equipment to target clock components, showing promise in reversing tumor immune theft with early-stage tests [50]

DISCUSSION

Tumor

a. Genomic instability and cell cycle indigestion: Chronic circadian miscalling deckhouse cell bicycle posts from DNA repair procedures. Core clock genes (e.g., clock, BMAL 1, per, croc) regulate the gene involved in apoptosis and DNA damage response. Their disintegration contains mutation and uncontrolled proliferation
b. Immune suppression: Disrupted rhythmic cytotoxic reduces cells and NK cell activity, reduces anti-tumor monitoring. Night-shift workers changed the cytokine profile, further compromising the immune defense.
c. Metabolic/hormonal disaggregation: Cortisol (chopper at dawn) and melatonin (nonet) are important for the suppression of rhythm tumors. Melatonin stops the spread of tumors through antioxidants and anti-angiogenic effects, while cortisol controls inflammation. Their disgusting promotes a pro-tumor micro-verse.

The aggression of the tumor is unbreakable to the circadian integrity. Integrating neural-immune insights and correction constipation activities provides a roadmap for chronic-acquit. Multi-disciplinary collaboration-AI-powered scheduling, biomarker verification, and expanding target watch modulator-it is necessary to exploit circadian biology for cancerous results.

Evidence of Epidemic

Large-scale studies confirm that night-shift work increases cancer incidence (breast, prostate, colorectal) by 20–40%. IARC classifies shift work as "probably carcinogenic" (Group 2A), which exposes the circadian dissolution as a convertible risk factor. Jet lags and irregular sleep-flock cycles are equally correlated with poor pregnancy.

Cronos-Oncology Treatment Strategies

a. Chrono Chemotherapy: The administration of chemotherapeutics (e.g., 5-fluororasil, oxaliplatin) in optimal circadian stages increases efficacy and reduces toxicity. For example, evening infection of 5-FU alignment with peak DNA synthesis in cancer cells improve the targeting of the tumor.
b. Circadian Biomarker: The comfort-renovation cycle, core body temperature, and cortisol rhythm treat as a biomarker to personalize time. Weed able equipment enables real -time monitoring, optimizing drug delivery windows
c. Watch-targeted medical: Small molecules modifying the clock components (e.g., Rev-ARB agonist, CK 1 inhibitor) are in pre-prickly trials. These agents re-shape the peripheral oscillator, restricting anti-tumor immunity and metabolic homeostasis

AI-powered platforms [21, 45] and Crispr screen [20] represent innovative devices for the future of chrono-acquit. AI technologies can personalize the treatment program by analyzing circadian biomarkers and patient-specific rhythms, while Crispr-based functional screen allows searches of clock-related genetic weaknesses in cancer. However, effective clinical translation will require a multi-disciplinary approach, which will have to integrate to overcome challenges such as molecular biology, oncology, computational modeling, and bio -engineering. [16, 21, 40]

CONCLUSION AND RECOMMENDATION

AI-powered scheduling platforms and minimum invasive biomarker verification are required to integrate circadian-targeted treatments with traditional oncology. Multi-disciplinary collaboration will bridge the gaps in translating pregnancy in individual clinical regimens, eventually optimizing the ability of chrono-oncology to improve the results of cancer.

ACKNOWLEDGMENT

The author accepts the support of the Department of Computer Science and Engineering, International Islamic University Chittagong, and appreciates the contribution of global researchers, whose genomic data and epidemiological insights were important for this paper.

REFERENCES

A. B. Chan et al., "Wearable technology for real-time circadian monitoring in cancer patients," Sensors, vol. 21, no. 19, p. 6512, 2021. doi: 10.3390/s21196512.

A. Ballesta et al., "Personalized chronotherapy via wearable biosensors," NPJ Digit. Med., vol. 4, no. 1, p. 98, 2021. doi: 10.1038/s41746-021-00476-7.

A. E. Hoffman et al., "Melatonin receptor agonists in cancer therapy," Trends Pharmacol. Sci., vol. 44, no. 5, pp. 301–315, 2023. doi: 10.1016/j.tips.2023.03.001.

A. Gupta et al., "Circadian reprogramming of tumor-associated macrophages," Immunity, vol. 56, no. 6, pp. 1237–1251, 2023. doi: 10.1016/j.immuni.2023.05.004.

A. Knutsson et al., "Shift work and gastrointestinal cancers: A 10-year follow-up," Occup. Environ. Med., vol. 80, no. 3, pp. 163–170, 2023. doi: 10.1136/oemed-2022-108526.

A. Sancar et al., "Circadian regulation of chemotherapy toxicity," Proc. Natl. Acad. Sci. U.S.A., vol. 120, no. 18, p. e2211506120, 2023. doi: 10.1073/pnas.2211506120.

B. Zhu et al., "BMAL1-deficient macrophages promote tumor metastasis," Cell Rep., vol. 41, no. 5, p. 111573, 2022. doi: 10.1016/j.celrep.2022.111573.

C. R. Cederroth et al., "Circadian desynchrony and metabolic syndrome," Nat. Rev. Endocrinol., vol. 20, no. 2, pp. 75–88, 2024. doi: 10.1038/s41574-023-00898-1.

C. Vetter et al., "Circadian disruption and metabolic dysfunction in shift workers," Diabetes Care, vol. 45, no. 10, pp. 2387–2395, 2022. doi: 10.2337/dc22-1028.

D.-J. Dijk et al., "Circadian disruption and human health," N. Engl. J. Med., vol. 388, no. 18, pp. 1721–1732, 2023. doi: 10.1056/NEJMra2201336.

E. Gottlieb et al., "Tumor-specific circadian biomarkers via liquid biopsy," Nat. Commun., vol. 14, no. 1, p. 4321, 2023. doi: 10.1038/s41467-023-39965-6.

F. Gachon et al., "The circadian clock as a cancer therapeutic target," Science, vol. 374, no. 6568, pp. 648–654, 2021. doi: 10.1126/science.abd6453.

F. Levi et al., "Chrono-FLOIRI regimen in metastatic colorectal cancer: Phase II results," Ann. Oncol., vol. 35, no. 1, pp. 89–98, 2024. doi: 10.1016/j.annonc.2023.10.003.

F. Levi et al., "Circadian timing of anticancer drug delivery systems," Adv. Drug Deliv. Rev., vol. 192, p. 114642, 2023. doi: 10.1016/j.addr.2022.114642.

F. W. Turek et al., "Circadian disruption and cardiometabolic cancer risk," Circ. Res., vol. 132, no. 11, pp. 1429–1444, 2023. doi: 10.1161/CIRCRESAHA.123.321687.

F. Wei et al., "Circadian disruption and prostate cancer incidence in the UK Biobank," Brit. J. Cancer, vol. 127, no. 5, pp. 914–921, 2022. doi: 10.1038/s41416-022-01852-0.

G. Mazzoccoli et al., "Chrono-oncology clinical trial design," Cancers, vol. 13, no. 11, p. 2761, 2021. doi: 10.3390/cancers13112761.

G. Sulli et al., "Circadian regulation of DNA repair in cancer," Cell Rep., vol. 39, no. 7, p. 110819, 2022. doi: 10.1016/j.celrep.2022.110819.
G. Sulli et al., "Pharmacological targeting of circadian transcriptional networks," Cell Chem. Biol., vol. 30, no. 3, pp. 278–291, 2023. doi: 10.1016/j.chembiol.2022.10.003.
G. Wu et al., "CLOCK/BMAL1 regulates genomic stability in pancreatic cancer," Cancer Cell, vol. 40, no. 2, pp. 196–211, 2021. doi: 10.1016/j.ccell.2021.07.008.
IARC Working Group, "Shift work and light at night: Updated carcinogenicity assessment," Lancet Oncol., vol. 24, no. 6, pp. e232–e241, 2023. doi: 10.1016/S1470-2045(23)00188-3.
J. B. Hogenesch et al., "Therapeutic targeting of circadian clock components," Pharmacol. Ther., vol. 248, p. 108454, 2023. doi: 10.1016/j.pharmthera.2023.108454.
J. Bass et al., "Time-restricted feeding and cancer outcomes," JAMA Oncol., vol. 9, no. 4, pp. 512–519, 2023. doi: 10.1001/jamaoncol.2022.6083.
J. Richards et al., "CRY2 stabilization promotes tumor growth in lung adenocarcinoma," J. Clin. Invest., vol. 132, no. 15, p. e156374, 2022. doi: 10.1172/JCI156374.
J. S. Takahashi, "Molecular architecture of the mammalian circadian clock," Nat. Rev. Mol. Cell Biol., vol. 23, no. 4, pp. 227–241, 2022. doi: 10.1038/s41580-021-00418-9.
K. A. Lamia et al., "AMPK regulates circadian clock stability," Mol. Cell, vol. 81, no. 18, pp. 3689–3702, 2021. doi: 10.1016/j.molcel.2021.07.012.
K. B. Koronowski et al., "CK1δ/ε inhibitors resynchronize circadian clock and tumor suppression," Sci. Transl. Med., vol. 15, no. 684, p. eabo4539, 2023. doi: 10.1126/scitranslmed.abo4539.
K. Papantoniou et al., "Night shift work and breast cancer risk: A meta-analysis of 14 cohort studies," Cancer Epidemiol., vol. 84, p. 102356, 2023. doi: 10.1016/j.canep.2023.102356.
L. A. Solt et al., "Development of synthetic circadian modulators," J. Med. Chem., vol. 67, no. 4, pp. 2521–2535, 2024. doi: 10.1021/acs.jmedchem.3c02343.
L. S. Mure et al., "Peripheral circadian clocks in tumor stroma," Nat. Cell Biol., vol. 26, no. 2, pp. 198–210, 2024. doi: 10.1038/s41556-023-01312-8.
M. E. Hughes et al., "AI-driven chronotherapy optimization platforms," Nat. Biomed. Eng., vol. 7, no. 8, pp. 987–1001, 2023. doi: 10.1038/s41551-023-01038-w.
M. H. Hastings et al., "Circadian rhythms in health and disease," Science, vol. 372, no. 6545, p. eabd0823, 2021. doi: 10.1126/science.abd0823.
N. Cermakian et al., "Clock genes and cancer immunity," J. Immunother. Cancer, vol. 9, no. 7, p. e002926, 2021. doi: 10.1136/jitc-2021-002926.
N. Koike et al., "Transcriptional architecture of the circadian clock in cancer," Cell Metab., vol. 33, no. 9, pp. 1762–1777, 2021. doi: 10.1016/j.cmet.2021.08.012.
N. M. Kettner et al., "Circadian dysregulation promotes metastasis via immune evasion," Nat. Cancer, vol. 4, no. 4, pp. 456–471, 2023. doi: 10.1038/s43018-023-00526-x.

N. Ozturk et al., "REV-ERBα agonists induce tumor-specific apoptosis," Cell Death Differ., vol. 29, no. 7, pp. 1436–1449, 2022. doi: 10.1038/s41418-022-00928-x.
P. Crosby et al., "Insulin/IGF-1 drives circadian disruption in tumors," Nat. Commun., vol. 13, no. 1, p. 6074, 2022. doi: 10.1038/s41467-022-33709-8.
P. Pevet et al., "Melatonin: From chronobiotic to anti-cancer agent," Endocr. Rev., vol. 45, no. 1, pp. 1–28, 2024. doi: 10.1210/endrev/bnad028.
R. C. Anafi et al., "Machine learning for circadian phenotyping in oncology," Cell Syst., vol. 15, no. 5, pp. 380–391, 2022. doi: 10.1016/j.cels.2022.04.002.
R. Dallmann et al., "Chrono-PK/PD modeling of oxaliplatin in metastatic cancer," Clin. Pharmacol. Ther., vol. 112, no. 3, pp. 634–645, 2022. doi: 10.1002/cpt.2645.
S. Masri et al., "Circadian-hormonal crosstalk in tumor microenvironment remodeling," Trends Endocrinol. Metab., vol. 32, no. 10, pp. 807–819, 2021. doi: 10.1016/j.tem.2021.07.002.
S. Panda, "Chrono-nutrition and cancer prevention," Annu. Rev. Nutr., vol. 44, pp. 121–143, 2024. doi: 10.1146/annurev-nutr-062322-021140.
S. Sahar et al., "Metabolic oscillations in tumor cells," Nat. Metab., vol. 4, no. 12, pp. 1650–1663, 2022. doi: 10.1038/s42255-022-00679-6.
S. Sato et al., "CRISPR screens identify clock genes as synthetic lethal targets in p53-mutant cancers," Cell Metab., vol. 36, no. 1, pp. 88–102, 2024. doi: 10.1016/j.cmet.2023.11.010.
T. Karantanos et al., "Circadian clock modulation of checkpoint inhibitors," Cancer Immunol. Res., vol. 11, no. 6, pp. 730–745, 2023. doi: 10.1158/2326-6066.CIR-22-0654.
V. Blakeman et al., "Chrono-radiotherapy: A systematic review," Radiother. Oncol., vol. 163, pp. 219–230, 2021. doi: 10.1016/j.radonc.2021.08.019.
W. Ruan et al., "Circadian gene PER2 suppresses glioblastoma progression," Cancer Res., vol. 82, no. 20, pp. 3718–3732, 2022. doi: 10.1158/0008-5472.CAN-22-0099.
X. Li et al., "Chrono-modulated chemotherapy in colorectal cancer: A phase III trial," J. Clin. Oncol., vol. 41, no. 15, pp. 2801–2812, 2023. doi: 10.1200/JCO.22.02812.
Y. Lee et al., "Melatonin suppresses tumor angiogenesis via circadian clock modulation," J. Pineal Res., vol. 73, no. 1, p. e12802, 2022. doi: 10.1111/jpi.12802.
Z. Chen et al., "Rev-erbα agonists synergize with immunotherapy in triple-negative breast cancer," Cancer Discov., vol. 12, no. 8, pp. 1940–1957, 2022. doi: 10.1158/2159-8290.CD-21-1320.